Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. 2004 4(12):2001–6.Ĭahill BC, Somerville KT, Crompton JA, Parker ST, O’Rourke MK, Stringham JC, et al.
Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. 2006 12(19):3114–8.Īugustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. Zhou J, Fan J, Wang Z, Wu Z-Q, Qiu S-J, Huang X-W, et al. Anaemia, microcytosis and sirolimus-is iron the missing link? Nephrol Dial Transpl. Sofroniadou S, Kassimatis T, Goldsmith D. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Sirolimus is associated with impaired hematopoiesis in heart transplant patients? A retrospective analysis.
McDonald MA, Gustafsson F, Almasood A, Barth D, Ross HJ. Posttransplant anemia: the role of sirolimus. 1999 67(7):1036–42.įishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB. Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Molecular mechanisms of mTOR-mediated translational control. mTOR signaling in growth control and disease.
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Taxonomy of the producing streptomycete and isolation of the active principle. Rapamycin (AY-22,989), a new antifungal antibiotic.
0 kommentar(er)
